Author: ifox

Mainz Biomed MYNZ Receives a $25 Price Target (Possible Gains Of 272% From Current Prices)

H.C. Wainwright Price Target Here

Small Cap Exclusive has built a reputation of uncovering stocks with massive upside potential. Our research reports have uncovered some of the largest breakout stock alerts year after year.

We stand by our alerts, our 2023 alert tracker providing transparency. Click Here

Small Cap Exclusive’s much anticipated research report on Mainz Biomed is found below.

4 Catalysts That Could Send Mainz Biomed B.V. (NASDAQ: MYNZ) Soaring Past Wainwright’s $25 Price Target

#1 H.C. Wainwright Announces MYNZ is Undervalued with a Price Target of $25

#2 Technicals Reveal a Major Bounce Play Opportunity

#3 Mainz Biomed Is Generating Revenue

#4 Philanthropic Investing feels good

Before we go over the top 4 reasons, let’s get acquainted with Mainz Biomed.

Company Name: Mainz BioMed

Ticker: MYNZ

Exchange: NASDAQ

Website: https://mainzbiomed.com/investors/

Mainz Biomed Company Summary

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.

ColoAlert is currently marketed across Europe with an FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval.

Urgent: Pattern Detected

Small Cap Exclusive’s research department has uncovered a pattern with their news cycle.

Most investors react to a press release, however our largest breakout stock alerts have an over arching story hidden in the news cycle.

However, if you read between the lines, the press releases act as a road map to the future.

Found below is the important press releases signaling to savvy investors a future where Mainz Biomed could soar past $25.

Seeking Alpha’s research report echoes this sentiment with the quote below:

“The current data suggest that the approvals should occur. As such, I expect the share price to jump significantly.”

Our research department has provided the condensed press releases below that are pointing to the “big announcement” where massive price increases could take place in hours yielding a fortune for early investors.

We have highlighted the “road map” below where we found hidden in the press releases a foreshadowing of “the big announcement”.

We start with the announcement of March 2022 with the pivotal clinical trial design for ColoAlert concluding with the press release below, where they will begin commercialization throughout Europe. All press releases are located here.

Key Press Releases, When Will Be The “Big Announcement?”

Savvy investors have known for decades that corporations are sending messages to the trading public via press releases, can you detect the underlying message with their news cycle?

February 21, 2023

Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies

Announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe.

Simultaneously, the Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. (“SOCPRA”), to outright purchase IP, including a pending patent, associated with a portfolio of novel gene expression (mRNA) biomarkers that have demonstrated ability to detect CRC lesions, including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to this deadly disease.

Key Takeaway: Commercialized across Europe.

Mainz Biomed’s 

3/14/23

MYNZ share price weakness presents an opportunity to trade ahead of potential near-term catalysts. Shares dropped on Monday, possibly in sympathy with the Silicon Valley Bank fiasco. However, while MYNZ does list a Berkeley, California connection on its byline, this company is primarily based in Germany. Thus, financial exposure, if any, is more of a distraction than an MYNZ-specific event. Moreover, its significance is outweighed by the planned data releases expected over the next 90 days. 

Remember, all deposits have been guaranteed by the U.S. Government and made available Monday morning. Hence, investors shouldn’t expect disruption to cash flow, which is the lifeblood of biotech. In other words, everything at MYNZ has stayed the same. And with contagion the likely cause of its share price decline, paying attention to MYNZ’s fundamentals and potential catalysts in the crosshairs exposes an opportunity worth seizing.

February 15, 2023

Continued roll-out in Europe with onboarding of new lab partners

Announced today the establishment of commercial partnerships for ColoAlert with Marylebone Laboratory (Marylebone Lab LTD) and Instituto de Microecologia, two leading independent laboratories covering England and Spain.

ColoAlert, Mainz Biomed’s flagship product, a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC), is currently being commercialized across Europe and in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Takeaway: Covering England & Spain.

January 18, 2023

Patient Access Initiative Addresses €1 Billion Annual Market in Germany

Announced today the launch of a corporate health program in Germany for ColoAlert, its highly efficacious and easy-to-use screening test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. As a start, ColoAlert has been integrated into BGM (“betriebliches Gesundheitsmanagement”), a corporate health network providing services to employees at forty-eight of the fifty largest companies in Germany[1].

Key Takeaway: Germany

November 15, 2022

MAINZ BIOMED ANNOUNCES U.S. EXTENSION OF COLOFUTURE STUDY TO EVALUATE INTEGRATION OF NOVEL MRNA BIOMARKERS INTO COLOALERT

Announced today the initiation of eAArly DETECT, its U.S. extension of ColoFuture, the Company’s European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert, Mainz’s highly efficacious, and easy-to-use detection test for colorectal cancer (CRC) being commercialized across Europe and in select international territories. ColoFuture/eAArly DETECT are multi-center studies assessing the potential of these biomarkers to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC.

Key Takeaway: USA

August 16, 2022

ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites 

Announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets.

Key Takeaway: Consumer commercial program in Italy and the United Arab Emirates

March 31, 2022

MAINZ BIOMED COMPLETES SUCCESSFUL PRE-SUBMISSION PROCESS WITH THE U.S. FDA FOR COLOALERT’S PIVOTAL CLINICAL TRIAL

announced today that it has received supportive feedback from the U.S. Food & Drug Administration (FDA) on the Company’s pre-submission package profiling the potential pivotal clinical trial design for ColoAlert, its highly efficacious, and easy-to-use detection test for colorectal cancer (CRC).  As Mainz prepares to launch ColoAlert’s pivotal clinical trial, the Company is also pleased to announce the formal commencement of its reimbursement process for ColoAlert by scheduling an initial meeting with The Centers for Medicare and Medicaid Services (CMS) in April 2022. 

Key Takeaway: pivotal clinical trial design for ColoAlert

December 7, 2021

At-home Colorectal Cancer Diagnostic Test Now Available Online in Germany

Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test. German residents unable to obtain timely CRC screening via in-person physician visits, will be able to order ColoAlert directly to their home and receive highly accurate results within a maximum of nine working days.

Key Takeaway: Cancer Diagnostic Test Available Online In Germany

DECEMBER 14th, 2021

Mainz to co-brand ColoAlert with GANZIMMUN Diagnostics, one of the largest stool analysis labs in Germany with their 5,500 labs.

Mainz Biomed announced a partnership with leading diagnostics laboratory GANZIMMUN Diagnostics AG (GD), one of Europe’s leading laboratories for preventive and complementary medicine, for the commercialization in Germany of ColoAlert, Mainz’s unique, highly efficacious, and easy-to-use detection test for colorectal cancer.

Key Takeaway: 5,500 labs in Germany

Before we reveal “the big announcement” we are all waiting for MYNZ to release let’s review the methodical international network they are creating in the press releases above.

All the while Wall Street is dead asleep. That is exactly what Small Cap Exclusive has built it’s reputation on, the deep dive research delivered direct to our subscribers inbox before volume comes pouring in.

Early investing is where Warren Buffet created his wealth and we take pride in helping retail traders have the same edge as Berkshire.

Let’s review our catalysts now before we go over what we believe is “the big announcement” that will catapult MYNZ to record breaking gains.

The 4 Catalysts That Could Send Mainz Biomed B.V. (NASDAQ: MYNZ) To Wainwright’s $25 Price Target

#1 Undervalued Presenting Massive Upside Potential

#2 Technicals Reveal a Major Bounce Play Opportunity

#3 Mainz Biomed Is Generating Revenue

#4 Philanthropic Investing feels good

#1 Undervalued Presenting Massive Upside Potential

Lets start of with the upside potential, H.C. Wainwright has issued a price target of $25 HERE

From the current PPS that is a 270% gain! Savvy traders, Pay attention!

Mainz Biomed has a Market Cap of $121 Million but when you look at other companies that are in the space, you can see the value in this diamond in the rough.

We are very excited to see this kind of potential priced at such a low PPS and with a very small float at 12 Million shares outstanding.

Furthermore, Mainz plans on starting the FDA process shortly after their public listing.  Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to a market potential of over 52 million tests per year. 1 

Can you imagine what will happen to the price per share of MYNZ when they get approved? Let’s look at one of their competitors to see what actually did happen!

Take a look at Mainz Biomed’s competitor Exact Sciences Corporation NASDAQ

Today, the top non-invasive colorectal screening test technology is manufactured by Exact Sciences (NASDAQ:EXAS), which is a perfect success story that Mainz BioMed is currently seeking to recreate. EXAS is valued at $17 BILLION and trades at $60 PPS! 

Could you imagine if MYNZ is trading at those PPS in the near future? That would be almost 1,000% gains, like turning $10,000 into $100,000. 

We do apologize, we tend to get excited about companies that are showing massive potential in a philanthropic industry. Invest and possibly make money while saving lives, it’s the cornerstone of the capitalism that Adam Smith promoted. 

Did you see the EXAS’ share price back in 08’ it fell to less than one dollar. Essentially, investors were basically saying Exact was worthless. But in June 2009, an announcement of a mutual collaboration and licensing agreement between Exact Sciences and the Mayo Clinic turned the company’s fortunes around.

Worth mentioning again, hint hint, “In June 2009, an announcement of a mutual collaboration and licensing agreement between Exact Sciences and the Mayo Clinic turned the company’s fortunes around.”

However, it was in 2014 when the FDA approved Cologuard for use as a non-invasive colorectal cancer screening test, and the test’s inclusion in multiple national guidelines that truly made the stock take off.

Hmm… Isn’t Mainz seeking FDA approval! See the correlation? I do and you should too.

For investors of EXAS who got in as recently as mid-2016 have already seen their investment grow nearly 20x in just over 5 years. Today it’s worth nearly $17 billion USD.

20x Returns, that $10,000 would be $200,000

Here is the kicker, Mainz Biomed’s ColoAlert is designed to be easier to administer than Exact Sciences ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy. This is truly cutting edge medical testing at a fraction of the PPS of Exact Science.

MYNZ other competitor is Genescopy a privately help company making some moves

The reason I mention Geneoscopy is because this story is relevant, take a look at the investment level, $100M++!

Geneoscopy Inc. is a life sciences company focused on the development of diagnostic tests for gastrointestinal health, announced November 17th the closing of a Series B financing, raising a total of $105 million through a combination of debt and equity.

The round is led by previous investors Lightchain Capital and NT Investments. Other investors in the round include Morningside Ventures, Labcorp, Cultivation Capital, BioGenerator Ventures, and Innovatus Capital Partners. HERE

That is an example of just how large this industry is and how much money is available to fund it. It’s cancer and it has affected almost everyone in one way or the other.

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing, for a bounce play!

Amidst the massive international stock market pull back, MYNZ PPS has been reduced by almost 50% and has created a clear consolidation pattern. See below

This is where Small Cap Exclusive shines! We issue research reports uncovering massive upside potential. There is a clear bottom in October of last year with a 30% run, then pulls back and consolidates again. We have seen this pattern over and over again and this stock should explode once the big announcement is made.

It is important to note, that MYNZ has created a stable base over the last 6 months reducing the downside risk, this is the exact point we issue research reports. Reduced risk with massive upside potential.

#3 Mainz Biomed B.V.  Is Generating Revenue

ColoAlert has received CE accreditation and is approved for sale in Europe.1  European sales will provide near-term revenue potential, while they prepare for entry into the US market. Just last month, Mainz Biomed announced the launch of ColoAlert.de, an ecommerce store providing Germans direct access to its ColoAlert colorectal cancer (CRC) screening test.

This is significant, DTC (direct to consumer) test to see if you have cancer which will allow you to catch it early and have a 90% survival rate. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.

ColoAlert is designed for profitability, rapid commercial uptake, and broad consumer acceptance. The fact that Mainz Biomed is generating revenue in Europe and will be entering the US market with FDA approval is a massive sign for things to come. Make sure you keep MYNZ on your watchlist because the potential is substantial.

#4 Philanthropic Investing – possibly turn an amazing profit while helping people

It is rare for investors to be able to possibly have a home run  return on an investment while helping to alleviate senseless deaths with the 2nd most deadly form of cancer.Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%. However, only about 4 out of 10 colorectal cancers are found at this early stage. When cancer has spread outside the colon or rectum, survival rates are lower.

90% survival rate if detected early, guess what, ColoAlert detects early stage colon cancer. There is a solution and it is ready to come to market in the USA with FDA approval.

Why is Mainz Biomed your cake and icing for investors?

1. 1. ColoAlert Holds Potential as a Blockbuster Early Detection Test for Colorectal Cancer. Far less senseless deaths in regards to colon cancer!
   2. Mainz BioMed protects its intellectual property through trade secrets to control all critical reagents, processes and formulations. Protecting intellectual property is important for market capitalization!
   3. Mainz Biomed MYNZ is developing proprietary genetic testing methods for pancreatic cancer. Once the distribution channel is developed, offering multiple products creates more than one revenue stream! 
   4. Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity. Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.

We have presented the necessary research and now we are ready to unveil what our research is pointing to, “the big announcement”.

On December 6, 2022 MYNZ announced approval from an independent Institutional Review Board (IRB) for the protocol ReconAAsense, the Company’s U.S. pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer (CRC).

Mainz Biomed has been conducting this study for over a year, which will form the basis of the data package to be submitted for review by the U.S. Food and Drug Administration (FDA) to achieve marketing authorization.

ReconAAsense is a prospective clinical study that will include approximately 15,000 subjects from 150 sites across the United States. The study objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and advanced adenomas (AA).

We believe the studies will come back positive and will be released soon. Mainz Biomed has been methodically making strategic moves that act as a harbinger of things to come.

We are already diving deeper into this for our second research report on the impact on PPS when the announcement comes. To receive this exclusive report before our publication, sign up below.

Let’s recap why Mainz Biomed MYNZ could be, THE massive breakout of 2023!

#1 MYNZ is Undervalued  

#2 Mainz Biomed B.V. (NASDAQ: MYNZ) Chart Looks Amazing!

#3 Mainz Biomed B.V.  Is Generating Revenue

#4 Philanthropic Investing feels good

It is a rare opportunity in this world to have this kind of investment opportunity while also funding the act of saving lives. This is an easy fix, detect the 2nd most dangerous form of cancer early and you have a 90% survival rate. ColoAlert is the answer, we just need to stop what we are doing and place it on your watchlist, today!

 Happy Trading and remember, never try to catch a falling knife!

Condensed Disclaimer

Small Cap Exclusive has been hired by Awareness Consulting for a period beginning on February 24, 2023 to publicly disseminate information about (MYNZ) via website and email. We have been compensated $116,000 USD to profile MYNZ for one month. We will update any changes to our compensation. Full Disclaimer

Therma Bright (TBRIF) Gains 29% Amidst Breaking News

Since Therma Bright TBRIF announced they secured the license for Digital Cough Technology, the stock has been on a steady climb up.

Here are the Top 3 catalysts that could send TBRIF up 200%++ in the next 3 months:

• Technologies are disruptive in a $21 billion market
• Multi-channel market penetration strategy
• Chart is bullish

History of Massive Runs

Where did we come up with 200%?

The 52 week high is $.21 and at the current prices that would represent 200% gains.

Check Out This Run

Date: October 24th 2022

PPS: $.039

PPS on 11/7: $.101

Gains: 159%

Small Cap Exclusive has built a reputation of uncovering stocks with massive upside potential. Our research reports have uncovered some of the largest breakout stock alerts year after year.

We stand by our alerts, our 2023 alert tracker providing transparency. Click Here

Small Cap Exclusive’s much anticipated research report on Therma Bright is found below.

[clickfunnels_embed height=”320″ url=”https://chrisputnam1229.clickfunnels.com/optin1677276397943″ scroll=”yes”]

(OTC:TBRIF) Therma Bright has so many catalysts that could send it parabolic it was difficult to finalize the top 3 catalysts found above, so we will open this research report with the honorable mention!

Therma Bright’s Other Explosive Catalysts

• Recent news has has created massive increases in share volume in the US market.
• TSX, Canadian exchange, is also having the same changes in trends, volume and PPS.
• This is a classic momentum play, all the indicators are pointing to it.
• The chart looks like Warren Buffet grabbed chalk, went to the chalk board, turned to the class and said, “this is a bullish trend line, this is breakout pattern, this is a momentum play and a possible short squeeze catalyst.” all in one chart!

]Why is Therma Bright trading at 49X trading volume?

News below is a game changer:

Therma Bright announced that it has finalized and signed the exclusive worldwide licensing rights to market and sell AI4LYF’s Digital Cough Technology (DCT). DCT can accurately and almost instantaneously detect multiple respiratory diseases, including COVID-19, simply and efficiently through a smartphone app, anytime, anywhere.

Pay attention!

Therma Bright is methodically releasing incredible press releases possibly setting up a massive run similar to the last bullish move from $.039 to .1010 representing a 159% increase in share price.

Notice a trend in the news cycle below?

March 1st – Announced The Appointment of Dr. John Patton as Chairman, most notably he was the co-founder of Inhale/Nektar (NKTR) achieved a US $2.1bn valuation on NASDAQ. link

Feb 23 – TBRIF Reports on Progress of Inretio’s Novel Clot Removal Device for Stroke Treatment link

Feb 16 – Therma Bright Secures Exclusive License Agreement for AI4LYF’s Patent-Pending Digital Cough Technology (DCT) to Detect Respiratory Diseases Link

Jan 19 – Therma Bright to invest up to US$2.5M in developer of a groundbreaking ischemic stroke treatment Link

Dec 1, 2022 – TBRIF invests in novel treatment using inhaled statins to treat respiratory conditions Link

Let’s do a quick summary on TBRIF before we jump into the catalysts.

Therma Bright Company Summary

Company Name: Therma Bright, Inc.

Ticker: TBRIF

Exchange: OTC

Website: https://www.thermabright.com/

Therma Bright Company Summary:

Therma Bright, developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today’s most important medical and healthcare challenges.

During the research process many investing principles that are a hallmark of a an explosive trade became clear in regards to Therma Bright.

However, we are going to focus on just three of the numerous unique investing propositions.

So, without further delay, here are the top 3 catalysts that could ignite parabolic growth with TBRIF.

Before we review #1 Catalyst, their technology suite, let’s review how the catalysts above could generate parabolic growth.

As mentioned above, Therma Bright trades on the OTC market which indicates the incredible upside potential if just one of their revolutionary products captures the market share warranted.

It gets better, they have strategically created two paths to revenue, institutional focus and direct to consumer.

More on that later, then to top it off the chart just broke through resistance and is appearing to be setting up for another massive run.

ADD UP ALL THE POSITIVES then add in that their technologies are innovative, have massive demand in the marketplace and are disruptive in a $21 billion market.

Digital Cough Technology (DCT)

Artificial intelligence, smart phones, algorithms, we live in an amazing time and Therma Bright very well could become a household name with their Digital Cough Technology.

In lay terms, imagine an application that has thousand of recorded coughs on a server. Next, those coughs are denoted and attributed to a certain illness or disease. Third step, develop a mobile app utilizing your microphone to record your cough. Finally, the application performs a search query to detect an illness or disease in the library of coughs.

Wow, just wow the times we live in! The icing on the cake is, you have an opportunity to take advantage of this amazing technology if you choose to invest in Therma Bright (OTC:TBRIF). Look at the amazing press on DCT below:

Press Announcing DCT Licensing

February 16th

Therma Bright announced that it has finalized and signed the exclusive worldwide licensing rights to market and sell AI4LYF’s Digital Cough Technology (DCT). DCT can accurately and almost instantaneously detect multiple respiratory diseases, including COVID-19, simply and efficiently through a smartphone app, anytime, anywhere. The exclusive license agreement also will allow Therma Bright to develop the DCT solution for other respiratory diseases, such as asthma, pneumonia, bronchiolitis, and chronic obstructive pulmonary disease.

Statins

Statins traditionally have been used to treat cholesterol but there has been significant studies in the efficacy in treating treat respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD), and acute lung inflammatory diseases, including those caused by COVID-19. Please review this study to gather a better insight in the incredible novel technology Therma Bright just acquired. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836012/

In December Therma Bright announced that it has entered into an agreement to acquire an interest in a novel technology utilizing inhaled statins to treat respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD), and acute lung inflammatory diseases, including those caused by COVID-19.

Research from the University of California Davis School of Medicine on “inhaled statins” to treat the acute and chronic respiratory inflammatory mechanisms associated with asthma, COVID-19, and other respiratory conditions has yielded promising results, according to Therma.  

Inretio

It keeps getting better, they announced a SPA (Share Purchase Agreement) with Inretio Ltd. (“Inretio”) for its innovative protective blood clot retriever technology.

Therma Bright has the right to invest up to USD $2,000,000 in cash and USD $500,000 in Therma Bright shares to earn up to 25% in Inretio Inc., subject to TSX Venture Exchange approval.

Inretio is developing a medical device called PREVA™ to treat ischemic stroke.

The PREVA™ clot retriever is a groundbreaking medical device that will change the way ischemic strokes are treated.

It is the first and only protective clot retriever that uses a distal basket. The device’s unique PREVA™ basket “ensnares” the clot, encapsulating it and protecting the brain from any sub-clots breaking off during the thrombectomy procedure.

This ensures the complete removal of the clot and its fragments, leading to more successful revascularization of the brain which can prevent further damage and complications. The PREVA™ clot retriever is a game-changing technology that has the potential to significantly improve outcomes of clot removal procedures for stroke patients.

Venowave

The Venowave is a circulation booster designed to improve circulation in the lower extremities.

The Venowave is a medical compression pump that is lightweight, compact, battery operated, designed to treat and alleviate the symptoms associated with poor circulation. When worn firmly on the calf, the Venowave produces a wave form motion forcing blood from the feet and legs back to the heart. This increase in blood flow draws oxygen to wound and ulcer sites, prevents blood pooling and clotting, and alleviates symptoms of Post Thrombotic Syndrome and other Chronic Venous Insufficiencies.

Therma Bright has implemented a multi-channel market penetration strategy that doubles their opportunity at success and can double their revenue.

You might be asking right now, what is a multi-channel market penetration strategy? In lay terms, Therma Bright is institutionally focused while consumer driven, a rare double threat that is similar to a unicorn when referencing international commerce.

Let us explain this concept in greater detail, because it is important. You don’t buy Tylenol from McNeil Consumer Healthcare you purchase it from CVS, their distributor. Similarly, you don’t buy Nyquil from Proctor & Gamble, you pick it up Harris Teeter. Therma Bright is making a massive commitment to operate in both models, intuitional and dtc. For a brief description of both models, look below.

Institutional: Hospitals, pharmacies, HMOs and the VA to mention a few. The pros with this model is massive sales, streamline logistics, reduction in customer service, reduction in marketing, reduction in employees and reduced accounting expenses. The cons are, thinner margins and the tail wags the dog, meaning, if you lose a massive account that is 23% of your business, heads will roll and revenue comes crashing down.

Direct to Consumer: Otherwise known as DTC, is any company that penetrates a market with directly to the consumer rather than through a wholesale distributor, HMO as an example. The advantage with DTC is you have the ultimate control. You are fishing for yourself rather than depending on a sales agency essentially. Furthermore, your profit margins are higher as well. The cons are higher overhead and the pain of managing all the employees who oversee the customers you created through your direct marketing efforts. https://www.benepod.com/

Breakout Pattern Detected

The 3rd catalyst has so many facets, such as: breakout confirmation, Canadian volume skyrocketing, momentum and it’s consolidated and ready for it’s next move!

Breakout confirmation is clear as day in the chart below. There was resistance and consolidation from $.0425 to $.05, then boom, it catapulted through resistance reaching it’s 60 day high. More importantly, it has retraced, pulled back, and consolidating creating a bullish trend! The chart looks spectacular!

Canadian Volume – Therma Bright trades under the ticker (TSXV: THRM) on the TSX, mirroring the US market, volume is skyrocketing due to the news and the possible short squeeze. The short squeeze aspect of Therma Bright is the gasoline that the catalysts spark and then it may go parabolic, more on this later. If you look below, you will see the TSX chart with a similar bullish trend and volume spikes.

New Momentum – As seen in both charts above, volume has increased 4,900%, that is worth repeating, 4,900% increase in demand for this stock! Look at the screenshot below.

Worth noting, with all of this demand TBRIF still has almost 200% to get to their 52 week high and all signs point to the possibility of meeting and exceeding those numbers with the catalysts and the possible short squeeze that we will discuss shortly.

Consolidated under current prices – the last 70 days have been trading in a consolidation pattern creating a base then the move it made a few days creates a situation where there are modest gains and sustainable gains without creating a mass sell off. This action creates a bullish pattern and incredible stability in the trading activities.

In closing, look at these record breaking volume spikes, turn your attention to Therma Bright (OTC:TBRIF) right now, regret can be demoralizing and always remember, to the victor belongs the spoils.

[clickfunnels_embed height=”320″ url=”https://chrisputnam1229.clickfunnels.com/optin1677276397943″ scroll=”yes”]

Condensed Disclaimer

Small Cap Exclusive is owned and operated by King Tide Media, LLC, which is a US based corporation & has been compensated $60,000 from Therma Bright Inc. for profiling TBRIF. We own ZERO shares in TBRIF.

FULL DISCLAIMER

Massive IPO Stock Alert: Lucy Scientific (NASDAQ:LSDI) Announces It’s $7.5M IPO

Lucy Scientific manufactures therapeutic psychedelics and made a huge announcement, we will get to that soon.

The Global Psychedelics Market Is Expected To Reach almost $100 BN By 2029 Full Article

That is larger than the cannabis market segment, without a market leader.

Lucy Scientific has made some serious steps toward possibly dominating the market.

This is exciting investors, it is a second chance at the cannabis boom but bigger.

In case, you need a reminder of how crazy that ride was, the market grew by 250% in less than a year.

UPDATE:

Breaking News:

March 21, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) [NASDAQ:LSDI], an early-stage psychedelics manufacturing company, announced that it has entered into a definitive asset purchase agreement with Wesana Health Holdings Inc. (“Wesana”).

Lucy has agreed to acquire intellectual property and related assets for Wesana’s psilocybin and cannabidiol (CBD) combination investigational therapy, SANA-013, and Wesana’s supply of psilocybin which is sufficient to complete all near-term clinical studies.  The aggregate consideration comprises 1,000,000 shares of common stock and $570,000 in cash. The shares will be subject to a lock-up agreement whereby half of the shares will be released 9 months from closing, and other half will be released 14 months from closing. The transaction is also subject to Wesana’s shareholder approval and is expected to close in Q2 2023.

Small Cap Exclusive has built a reputation of uncovering stocks with massive upside potential, concentrating on IPOs and we have uncovered some interesting data on LSDI.

Our research reports have uncovered some of the largest breakout stock alerts year after year.

LSDI may even be the best yet. So put us to the test and put it on your watchlist.

We stand by our alerts, our 2023 alert tracker provides transparency. Click HERE

Small Cap Exclusive’s much anticipated research report on Lucy Scientific (NASDAQ:LSDI) is found below.

Top 3 catalysts that could send LSDI up 127%++ in the next month:

#1 The Chart

#2 IPOs Offer A Significant Upside Potential

#3 The Market Could Be As Big As Coffee

Lucy’s Other Explosive Catalysts

• Recent news has has not been covered by major financial news outlets, creating a unique opportunity.
• Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin. Press Release
• Files Amendment with Health Canada to Expand its List of Controlled Substances to Include Cocaine and Heroin Press Release

Why do we consider Lucy Scientific as a contender for the best stock of 2023?

Large announcements in the drug world is turning heads on Wall Street and it feels like 2017’s green boom with cannabis.

Wait until you see what we have uncovered!

Major Psychedelic Announcements:

2019: May 9th

Denver, Colorado became the first city in the United States to decriminalize the cultivation, possession and use of psilocybin mushrooms.

2019: June 5th

Oakland California decriminalized the cultivation, possession and use of plants or fungi containing psychedelic compounds including DMT, ibogaine, mescaline and psilocybin.

2019: September 4th

Johns Hopkins launched the Center for Psychedelic and Consciousness Research.  The center’s director, Roland Griffiths, said that researchers will focus on how psychedelics affect behavior, mood, cognition, brain function, learning, memory, and biological markers of health.

2019: November 22nd

The Food and Drug Administration granted Breakthrough Therapy designation to the Usona Institute for its psilocybin therapy for major depressive disorder.  Usona’s phase 2 clinical trials will include 80 volunteers at seven sites around the U.S. 

2020: October 22nd

In Vancouver, Canada Numinus Wellness Inc. harvested the first legal flush of psilocybin mushrooms by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s License.

2021: October 18th

Johns Hopkins Medicine was awarded a $3.9 million grant by the National Institutes of Health (NIH) for clinical research on psilocybin-assisted psychotherapy to treat tobacco addiction.

Let’s take a closer look at Lucy LSDI.

2023: March 23

Announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world.

The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’.

Lucy Scientific Discovery Company Summary

Company Name: Lucy Scientific Discovery

Ticker: LSDI

Exchange: NASDAQ

Website: https://www.lucyscientific.com/

Lucy’s Company Summary:

Lucy Scientific Discovery Inc. [NASDAQ:LSDI] an early-stage psychedelics manufacturing company that is focused on becoming the premier research, development, and manufacturing organization for the emerging psychedelics-based medicines industry.

Lucy maintains a Controlled Drugs and Substances Dealer’s License under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), more commonly known as a Dealer’s License, that was issued to Lucy by Health Canada’s Office of Controlled Substances.

This Dealer’s License authorizes the Company to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.

Before we review #1 Catalyst, their technology suite, let’s review how the catalysts above could generate parabolic growth.

As mentioned above, Lucy Scientific Discovery trades on the NASDAQ as an IPO, which indicates the incredible upside potential.

#1 The Chart

The chart has clearly broken out and is creating a bullish trend line. Start your research now before it is too late, just like the green boom.

#2 IPOs Offer A Significant Upside Potential

Facebook META acted the same way as most IPOs with hype. They get overbought, they pull back and then run like mad!

Lucy is following that same pattern and we believe it has created a bottom and has broken out clearly in the above image.

Look at what Motley Fool wrote about the massive opportunity FB provided, “The stock was offered at $38 per share via the IPO. Let’s assume you bought 132 shares for a total of $5,016 on May 18, 2012, and held all the way through to today. At today’s price of around $191 per share, those 132 shares would be worth $25,212, resulting in a market-beating five-bagger.”

Just like the cannabis boom, and Facebooks IPO, traders are being handed another possible monumental opportunity.

#3 The Market Could Be As Big As Coffee

The global mushroom market size was valued at USD 50.3 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 9.7% from 2022 to 2030. The increasing vegan population demanding a protein-rich diet around the globe is expected to be a key driver for the market over the forecast period. Mushrooms are considered a superfood owing to their nutritional contents. Mushrooms are packed with four key nutrients namely selenium, vitamin D, glutathione, and ergothioneine. These nutrients help mitigate oxidative stress and prevent or decrease the risk of chronic conditions such as cancer, heart disease, and dementia. Moreover, it offers a strong natural umami flavor, allowing consumers to reduce salt proportion in mushroom meals by 30-40%, thereby benefitting health.

The U.S. was the second-largest producer accounting for approximately 375 million kg in the year 2019. The production in the country is declining since 2017 and has declined by 11% from 2017 to 2019. Whereas the demand from end-users is growing, which has resulted in an increase in the prices by 6% in 2017-18 and by 3% in 2018-19. The U.S. government is continuously increasing import duties, which is also contributing to the higher prices of mushrooms. Mushroom is one of the protein-rich vegan sources as it offers nearly 3.3 g of protein per 100 g of serving. Meat has been a key source of protein in the western diet; thus, the population adopting a vegan diet is anticipated to prefer protein-rich vegan products to fulfill their daily protein requirements.

Condensed Disclaimer

Small Cap Exclusive is owned and operated by King Tide Media, LLC, which is a US based corporation & has been compensated $350,000 from Lucy Scientific Discovery Inc. for profiling LSDI. We own ZERO shares in LSDI.

FULL DISCLAIMER

FSD Pharma Inc. (HUGE) Is Bullish On ALL 19 Technical Indicators

FSD Pharma Inc. HUGE stock could be heading to the moon, look at this chart below!

Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:

#1 All Technical Indicators & The Chart Are BULLISH

#2 Canada Greenlighted Phase 1 Trial for Multiple Sclerosis

#3 The Stock Has A History Of Big MOVES

FSD Pharma Growing Systems Company Summary

Company Name: FSD Pharma Inc.

Ticker: HUGE

Exchange: NASDAQ

Website: https://fsdpharma.com/

Company Summary: FSD Pharma, Inc. is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

No need to really discuss this in great detail, this is incredibly rare to have all 19 technical indicators on Yahoo and Market Watch agreeing that this stock is BULLISH.

There are no Guarantees in the stock market BUT this is as close as we have ever seen!

Seeking Alpha wrote an amazing article on FSD Pharma Inc. (NASDAQ:HUGE) and we include an excerpt from it below.

• “The shares of Canadian biotech FSD Pharma (NASDAQ:HUGE) rose for the fourth consecutive session on Tuesday after announcing that Canada greenlighted its Phase 1 trial for multiple sclerosis candidate LUCID-21-302.
• Issuing a No Objection Letter (NOL), Health Canada has granted the regulatory nod to start the first-in-human clinical trial for LUCID-21-302 in the country, FSD (HUGE) said without detailing the estimated timeline for the study.
• “We will continue to work with Health Canada and other regulators worldwide to complete clinical investigations as soon as we can,” Chief Executive Lakshmi Kotra remarked.
• Preclinical studies have indicated the potential of LUCID-21-302 in the prevention of myelin degradation, which is believed to result in neurogenerative diseases such as MS, where there is damage to the myelin sheath in neuronal cells.
• The Toronto-based pharma announced in September that the US and Canadian regulators cleared its mid-stage trial for FSD201 to treat a form of pain caused by the abnormal functioning of the body’s mast cells called idiopathic mast cell activation (IMCA) syndrome.“

Press Release Below

February 7th 2023

TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announces the receipt of a No Objection Letter (“NOL”) from Health Canada regarding the Company’s proposed Phase 1 clinical trial of LUCID-21-302 (“Lucid-MS”), a novel drug candidate for the treatment of Multiple Sclerosis (“MS”). The NOL provides FSD Pharma with regulatory approval to move forward with the clinical trial in Canada.

Look at this BEAST, exploding from $1.36 to $4.09 representing 200% gains!

WOW, $17 to $154 representing almost 1,000% gains. Furthermore, the fact that it was at $154 pre-covid and supply chain difficulties reveals the MASSIVE potential of this burgeoning Wall Street darling!

Let’s recap!

Top 3 Reasons To Turn Your Attention To (NASDAQ: HUGE) Right Away:

#1 All Technical Indicators & The Chart Are BULLISH

#2 Canada Greenlighted Phase 1 Trial for Multiple Sclerosis

#3 The Stock Has A History Of Big MOVES

Happy Trading!

DISCLAIMER

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has not been compensated for profiling HUGE. We own ZERO shares in HUGE.

FULL DISCLAIMER

Friday Feb 3rd, All eyes on MDJH our low float momentum play!

Pull up MDJH now, super low float momentum play for Friday, tomorrow, Feb 3rd.

The float is super low at 1.4M shares!

This stock has a history of 100% gains with very low volume.

MDJH should be very active in the morning, so be ready!

The definition of a momentum play is:

when you buy a stock because the stock is moving big and you are hoping to scalp a quick gain if the move continues.

We think this is going to be “moving big” at the morning bell.

Remember, this stock moves very fast on a few trades.

So be ready tomorrow morning!

We have identified 2 catalysts revealing the hidden potential with MDJH.

Before we go over the catalysts, let’s do a quick summary on MDJM Ltd (NASDAQ: MDJH)

MDJM Ltd Company Summary

Company Name: MDJM Ltd

Ticker: MDJH

Exchange: NASDAQ

Website: http://ir.mdjmjh.com/

MDJM Ltd Growing Systems Company Summary:

Founded in 2002 and headquartered in Tianjin, China, Mingda Tianjin is an emerging, integrated real estate services company in China.

We primarily provide primary real estate agency services to our real estate developer clients, and provide, on an as-needed basis, real estate consulting services, and independent training services.

MDJH Has Two Catalysts That Could Send It To The Moon Tomorrow

#1 Low Float

#2 Small amount of volume makes it explode

LOW supply & HIGH Demand = Massive PPS Increases, it’s simple math!

Stock MDJH has ONLY 1.4M shares in the float.

Our last two alerts traded 1M shares each, that would almost be the WHOLE FLOAT!

Our subscribers have an amazing opportunity!

What do we mean by, “our subscribers have an amazing opportunity!”?

We love low float stocks because of their ability to MOVE.

They provide great upside opportunities for day traders.

What is a “low float stock”?

Low float stocks are those with a low number of shares. Floating stock is calculated by subtracting closely-held shares and restricted stock from a firm’s total outstanding shares. Closely-held shares are those owned by insiders, major shareholders, and employees.

MDJH has only 1.4M shares in the float.

While the average NASDAQ float we normally feature is 10M shares, 10X higher!

This stock has very little supply of shares in the market and our subscribers normally create a large amount of demand.

Remember, LOW supply & HIGH Demand = Massive PPS Increases, it’s simple math!

On August 2nd of last year MDJH traded around our average volume of 1.7M shares and went up almost 100%!

That day went like this, someone invested $10,000 and had $20,000 in just a few hours.

Again, our average alerts trade 1-2M shares

The last time MDJH had that kind of volume was in August and went up almost 100%!

Let’s Recap The Two Catalysts That Could Send It To The Moon Tomorrow

#1 Low Float

#2 Small amount of volume makes it explode

Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has not been compensated for profiling MDJH. We own ZERO shares in MDJH.

Full Disclaimer

Best Stocks of 2023: Buy Ratings for GoldMining (NYSE: GLDG)

Why is GoldMining (NYSE: GLDG) a strong buy target by these 3 analysts and could it be one of the best stocks of 2023? link

But before we get started, take a look at our last alerts, we are crushing the STREET!

We have 3 catalysts that have catapulted GLDG into the spotlight.

#1 The news is driving massive volume spikes!

#2 The chart is absolutely perfect and could be ready for a monster run.

#3 So many industry authorities issued a a “Buy Rating”

First and foremost, January’s news release is dynamite!

GoldMining Triples Gold Equivalent Inferred Resource Estimate To 1.45Mn Ounces At La Mina Project With La Garrucha Discovery

La Garrucha deposit adds approx. 1.0 million oz AuEq in the Inferred category and 0.2 million oz AuEq in the Indicated category

Updated Mineral Resource estimate inclusive of La Garrucha positions La Mina with 1.15 million oz AuEq Indicated and 1.45 million oz AuEq Inferred resources

The press release reads:

Jan. 23, 2023

Announced an updated Mineral Resource estimate (“MRE”) on its 100% owned La Mina Project located in Colombia.

The MRE includes a maiden resource estimate on the La Garrucha deposit which incorporates drilling completed by 2023.

Alastair Still, CEO of GoldMining, commented, “We are extremely pleased that the Company’s first exploration drilling program at La Mina has identified a significant discovery!”

“This exciting discovery has exceeded our expectations!”

Tim Smith, Vice President, commented, “The updated Mineral Resource estimate at La Garrucha represents an unqualified success for the Company!”

Read the full article here.

Take a look at this chart!

The next run will test the 3 month high based on technicals.

This should break through based on the technical indicators below:

Barchart was reporting these as triggered:

Short Term Indicators

• 20 – 50 Day MACD Oscillator
• 20 – 100 Day MACD Oscillator
• 20 – 200 Day MACD Oscillator

Medium Term Indicators

• 50 Day Moving Average
• 50 – 100 Day MACD Oscillator
• 50 – 150 Day MACD Oscillator
• 50-200 Day MACD Oscillator

Long Term Indicators

• 100 Day Moving Average
• 150 Day Moving Average
• 200 Day Moving Average

The website also shares its all-important “Trend Seeker” composite indicator is triggered.

Watch these technicals closely this week.

TipRanks Reported $5.25 Target Provides Over 320+% Potential Upside

GLDG is displaying a ton of potential upside to this $5.25 target.

In fact, that’s 320+% potential upside.

Now, I’m not saying this profile is going to surge to $5.25 this week, but the potential upside needs to be noted.

Plus, don’t forget, GLDG has a 52-week high over $2.00 which may also help signal that this NYSE American profile could be undervalued from current levels.

Also, GoldMining (NYSE: GLDG) has yet another strong buy target by these 3 analysts and could it be one of the best stocks of 2023? link

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has been compensated $7,500 from East Coast Media, LLC for profiling GLDG. We own ZERO shares in GLDG.

Full Disclaimer

Best Stocks of 2023 Best NASDAQ Stocks, delivered to YOU

Delivering the best NASDAQ stocks of 2023 yielding on average double digit gains.

We believe in transparency!

We post every pick so you can feel confident in our 💎 featured breakout alerts.

Small Cap Exclusive’s Best NASDAQ Stocks of 2023:

Best Stock of 2023 Avalon GloboCare Corp. (ALBT)

Ticker: ALBT

Corp Name: Avalon GloboCare Corp.

Date Of Alert: March 6th

Alert Price: $2.14

Date Of High: March 6th

High After Alert: $3.87

Gain/Loss: Gain of 81%

Best Stock of 2023 Mainz Biomed (MYNZ

Ticker: MYNZ

Corp Name: Mainz Biomed

Date Of Alert: February 15th

Alert Price: $7.35

Date Of High: February 15th

High After Alert: $7.50

Gain/Loss: Gain of 17%

Best Stock of 2023 FSD Pharma Inc. (HUGE)

Ticker: HUGE

Corp Name: FSD Pharma Inc.

Date Of Alert: February 9th

Alert Price: $1.44

Date Of High: February 11th

High After Alert: $1.68 (52 Week High)

Gain/Loss: Gain of 17%

Best Stock of 2023 MDJM Ltd (MDJH)

Ticker: MDJH

Corp Name: MDJM Ltd

Date Of Alert: February 3rd

Alert Price: $1.80

Date Of High: February 3rd

High After Alert: $2.10

Gain/Loss: Gain of 17%

Best Stock of 2023 Uranium Royalty Corp. (UROY)

Ticker: UROY

Corp Name: Uranium Royalty Corp.

Date Of Alert: February 1

Alert Price: $2.80

Date Of High: February 1st

High After Alert: $2.93

Gain/Loss: Gain of 5%

Best Stock of 2023 Stock GoldMining Inc. (GLDG)

Ticker: GLDG

Corp Name: GoldMining Inc.

Date Of Alert: January 31st

Alert Price: $1.15

Date Of High: February 1st

High After Alert: $1.24

Gain/Loss: Gain of 7%

Best Stock of 2023 Stock Avalon GloboCare Corp. ALBT

Ticker: ALBT

Corp Name: Avalon GloboCare Corp

Date Of Alert: January 8th

Alert Price: $4.01

Date Of High: January 9th

High After Alert: $4.47

Gain/Loss: Gain of 11%

Best Stock of 2023 Stock Clearmind Medicine Inc. CMND

Ticker: CMND

Corp Name: Clearmind Medicine Inc.

Date Of Alert: January 4th

Alert Price: $3.26

Date Of High: January 9th

High After Alert: $5.10

Gain/Loss: Gain of 56%

The alert: https://smallcapexclusive.com/clearmind-medicine-inc-nasdaq-cmnd-is-disrupting-the-pharmaceutical-industry-with-a-revolutionary-treatment/

Best NASDAQ Stock Kaival Brands Innovations Group, Inc. (KAVL)

Ticker: KAVL

Corp Name: Kaival Brands Innovations Group, Inc.

Date Of Alert: December 6th

Alert Price: $.98

Date Of High: December 8th

High After Alert: $1.10

Gain/Loss: Gain of 11%

Best NASDAQ Stock LuxUrban Hotels Inc. (LUXH)

Ticker: LUXH

Corp Name: Kaival Brands Innovations Group, Inc.

Date Of Alert: November 30th

Alert Price: $1.40

Date Of High: January 11th

High After Alert: $1.80

Gain/Loss: Gain of 28%

Our commitment to delivering the best stocks of 2023:

Facebook LINK

How do we deliver the best stocks of 2023?

Fast & Actionable Alert Delivery

As soon as a potential trade presents itself, our team works to send out the trade alert quickly, delivering high quality alerts for traders and investors.

Unlock Your Best Trading Potential

The best NASDAQ Stocks are more accessible than ever before. Get started with just a smart phone in your hand, use the tools we provide to enhance your trading level.

Top Picks From Curated Watchlists

We spend our time scanning the market and analyzing our watchlists looking for the best trade ideas to alert our members. Our team does this so you don’t have to!

Full DISCLAIMER

Partial Disclaimer

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has been compensated $5,000 by Life water Media on Jan 9 for ALBT, $5,000 from Life Water Media for profiling CMND, KAVL on Dec 6 paid $8,000 by Awareness Consulting. LUXH – Nov 30 – not compensated. We own ZERO shares in any above mentioned stock.

We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

We publish the Information on our website, smallcapexclusive.com and in newsletters, text message alerts, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer and / or third party paying us. Our publication of the Information is known as a “Campaign”. This information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. Typically, the trading volume and price of a Profiled Issuer’s securities increases after the information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer trading losses if they purchase the securities of a Profiled Issuer late in a Campaign.

Sharps Technology, Inc. (NASDAQ: STSS) Has An Accelerated Near-Term Path Product For The Commercialization & Accelerated Revenue Growth!

With An Accelerated Near-Term Path For Product Commercialization And Expanded Manufacturing Capacity, Sharps Technology, Inc. (NASDAQ: STSS) Will Have The Ability To Support The Industry With Innovative, Market Leading Injectable Drug Delivery Solutions And Accelerate A Path Towards Revenue Growth.

Newly NASDAQ-traded Sharps Technology, Inc. (NASDAQ: STSS) offers innovative injectable syringe solutions to a global healthcare crisis that is not being talked about nearly enough.

• Most syringes waste a significant amount of injectable medicine which is thrown away with the used needle/syringe.
• This adds cost and reduces the availability of life-saving injectable drugs for us all. Whether we are looking at a pandemic response, hard-to-manufacture drug products, or managing long-term chronic illness, we can’t afford to waste this precious supply.
• The problem is sufficiently worrisome that the Federal Government is passing new legislation (January 1, 2023) requiring pharmaceutical companies to pay financial penalties for injectable drugs which are thrown away with the syringe and not injected into the patient.

Sharps Technology Company Summary

Company Name: Sharps Technology, Inc.

Ticker: STSS

Exchange: NASDAQ

Website: www.sharpstechnology.com

Sharps Technology Company Summary:

Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems.

The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features.

These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use.

Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing.

The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.

Sharps Technology has agreed to manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.

Jan. 10, 2023

Announces the advancement of the Company’s specialized prefillable syringe (“PFS”) system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.

Braden Miller, Sharps Director of Product Management, commented, “Sharps has developed an alternative high-quality solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution compared to traditional glass syringe systems.

These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which can eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors.

The ability to produce these innovative products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance and safety when compared to similar glass syringe products. We look forward to introducing this line of next generation products to the market.”

Sharps Technology commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.

Dec. 20, 2022

Announced they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.

The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.

Sharps innovative syringe designs provide a beneficial set of features and advantages for the healthcare industry.

These syringe product features include a combination of ultra-low waste, passive and active safety, and reuse prevention.

By combining all these features and building them into a portfolio of syringe offerings, it will create product platforms that can help drive down the cost of healthcare treatments.

Sharps Technology signed of a distribution agreement with partner Nephron Pharmaceuticals

Dec. 13, 2022

Announced the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.

“This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals,” commented Robert Hayes, Sharps Technology CEO. “The timing is perfect in that we are expanding our ability to supply innovative drug delivery systems at a point when the market is in demand for them. Through this distribution plan, Sharps Technology will be able to deliver increased capacity, driving growth for one of the high value product segments of our business.”

• Each year almost  20 billion injections are administered, globally and the World Health Organization (WHO) are advocating for the use of low waste syringes, with passive safety devices which engage automatically and have auto disable features.
• STSS anticipates signing its first product orders any moment now this development will represent a huge milestone for this recently debuted NASDAQ company, and should provide them with a solid foundation for growth.
• The company has raised $16M to scale operations in the coming quarters as they begin to meet the strong and growing demand for smart safety syringes

The global vaccines market is projected to grow from $61.04 billion in 2021 to $125.49 billion in 2028 at a CAGR of 10.8% in the forecast period, 2021-2028.

Vaccines are the most powerful and cost-effective way to protect billions of people in the world, and according to the WHO, immunization awareness and government initiatives have helped prevent 2-3 million deaths a year.

The Covid-19 outbreak led to a shutdown of syringe manufacturing which in turn led to a supply shortage at a global scale.

Mergers and acquisitions of companies such as STSS are highly attractive and are providing the needed innovation to the vaccine market.

The rise in the need for vaccinations and immunizations, plus a surge in the geriatric population, an increase in the number of surgical procedures, as well as a rise in chronic diseases have contributed to a demand for syringes.

Specialty Syringes – Vial Application 

• Global Smart Syringe Market @ $14 billion USD by 2026 w10.0%+ CAGR 
• Types: Auto-Disable Syringes and Safety Syringes
• Applications: Vaccination and Drug Delivery
• End Users: Hospitals, HMOs and Clinics
• Target Markets: North America, Europe, and ROW
• Sharps Technology listed as a supplier

The Pre-Filled Syringe (PFS)/Ready- To- Fill (RTF) syringe product segment will be a priority for the company through its collaboration with Nephron, and is expected to be a gamechanger for the company.

PRE-FILLED SYRINGES MARKET

• Pre-filled syringes have emerged as one of the fastest-growing choices for unit-dose medication as the pharmaceutical industry seeks new and more convenient drug delivery methods.
• With PFS/RTF syringes, pharmaceutical companies are able to minimize drug waste and increase product life span, while patients are able to self-administer injectable drugs at their home instead of the hospital.

Ready-To-Use – Pre-Filled Syringes:

• Types: Plastic and Type I B/S Glass 
• Applications: Vaccines, Diabetes, Complex High Value Therapies (Gene-Therapy)
• End Users: Branded Pharma, CMOs, and Biologics
• Target Markets: North America

There is a growing demand for efficient and easy-to-use drug delivery devices and increasing efforts of healthcare professionals to reduce hospital errors are the principal factors driving the market growth.

STSS announced over the summer that it had completed its acquisition of Safegard Medical’s syringe manufacturing facility in Hungary.

The manufacturing facility is located 2 hours from Budapest (160km from Budapest Airport)

• 40,000 sq. ft. factory on 250,000 sq. ft. site
• 20-year history of safety syringe manufacturing
• FDA registered since 1999
• ISO 13485 certified
• CE Mark approved products
• Injection molding and assembly expertise
• ETO on-site sterilization capacity

“The acquisition of our first manufacturing facility is an important milestone in our transformation from an R&D-focused enterprise to revenue-generating commercial operations. With the acquisition now complete, with the addition of further assembly and manufacturing capacity, our team is confident we can deliver world-class products to meet the strong and growing demand for smart safety syringes, a market forecasted to reach $14 billion globally by 2026.”

Robert Hayes, CEO of Sharps Technology

IN SUMMARY

Sharps Technology, Inc. (NASDAQ: STSS) is the newest player in the drug delivery device market to go public and could see tremendous blue-sky growth in its future as it continues to ramp up its commercialization efforts.

• The Company recently announced a significant partnership with Nephron Pharmaceuticals with an anticipated launch into the market in early 2023.
• STSS anticipates shipping first orders of vial draw product by the beginning of 2023 and ready to fill product in mid-2023 to create initial revenue in 2023 and profits in early 2024.
• With the global shortage of syringes that comply with the World Health Organization (WHO) requirements, there is a strategic opportunity for STSS to take market share and support the healthcare industry with a better drug delivery platform.
• The combination of features and benefits for the Sharps products will save lives and eliminate the waste of critically needed medical treatments and therapies for the industry!
• There’s a key opportunity for STSS to grab a big piece of the market with its proprietary smart safety syringe technology designed to eliminate two million potentially infectious accidental needlestick injuries, as well as billions of dollars in medicine wasted with today’s inefficient syringes with their low-dead space feature.

To reiterate, the company anticipates signing its first distributor agreement during the fourth quarter of 2022, which could be at any moment!

FULL DISCLAIMER